Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

5PSQ-033 Abstract withdrawn

View Full Paper
Ask AI
Bookmark
Share

Authors

FAFM Atsina

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

FM Atsina (2024) studied this question.

synapsesocial.com/papers/68e76a16b6db6435876df2dchttps://doi.org/10.1136/ejhpharm-2024-eahp.367
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-067 Drug utilisation profiles of advanced therapy medicinal products: a real-world evidence study2024
  2. 22SPD-002 Evaluation of the effectiveness and related cost of oncology drugs used in special situations, in a third-level university hospital2024
  3. 3Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica2025
  4. 41ISG-001 Analysis of the use of oral oncology targeted therapies in a region of Spain2024
  5. 552 Access to non-standard treatments: Insights from a UK-wide review of adult brain tumour services (2024-2026)2026